Oxaliplatin cas no:61825-94-3
Synonyms: Eloxatin;1-OHP;(1R,2R)-cyclohexane-1,2-diamine; oxalic acid; platinum(+2) cation;Eloxatin (TN);Trans-l-diaminocyclohexane oxalatoplatinum;Platinum, (1,2-cyclohexanediamine-N,N)(ethanedioato(2-)-O,O-, (SP-4-2-(1R-trans))-;Platinum, [ (1R,2R)-1,2-cyclohexanediamine-.kappa.N, .kappa.N][ethanedioato(2-)-.kappa.O1,.kappa.O2]-,(SP-4-2)-;(SP-4-2-(1R-trans))-(1,2-Cyclohexanediamine-N,N)(ethanedioato(2-)-O,O)platinum;RP 54780;Oxalatoplatinum;Oxaliplatin EP5;
NameOxaliplatin
CAS61825-94-3
SynonymsEloxatin;1-OHP;(1R,2R)-cyclohexane-1,2-diamine; oxalic acid; platinum(+2) cation;Eloxatin (TN);Trans-l-diaminocyclohexane oxalatoplatinum;Platinum, (1,2-cyclohexanediamine-N,N)(ethanedioato(2-)-O,O-, (SP-4-2-(1R-trans))-;Platinum, [ (1R,2R)-1,2-cyclohexanediamine-.kappa.N, .kappa.N][ethanedioato(2-)-.kappa.O1,.kappa.O2]-,(SP-4-2)-;(SP-4-2-(1R-trans))-(1,2-Cyclohexanediamine-N,N)(ethanedioato(2-)-O,O)platinum;RP 54780;Oxalatoplatinum;Oxaliplatin EP5;
Molecular FormulaC8H14N2O4Pt
Molecular Weight397.28576
AppearanceWhite Crystalline Solid
Globally Harmonized System of Classification adn Labelling of Chemicals(GHS)
Hazardclass6.1(a)
Hazard Xn: Harmful;
Risk R36/37/38;R40;R42/43
Safety
Safety Information of Oxaliplatin (CAS NO.61825-94-3):
Hazard Codes: Xn
,Xi
Risk Statements: 36/37/38-40-42/43??
R36/37/38:Irritating to eyes, respiratory system and skin.?
R40:Limited evidence of a carcinogenic effect.?
R42/43:May cause sensitization by inhalation and skin contact.
Safety Statements: 26-36
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.?
S36:Wear suitable protective clothing.
RIDADR: 2811
WGK Germany: 3
RTECS: TP2275850
HazardClass: 6.1(a)
PackingGroup: II
Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
mouse |
LD50 |
intraperitoneal |
19800ug/kg (19.8mg/kg) |
? |
Drugs of the Future. Vol. 14, Pg. 529, 1989. |
rat |
LD50 |
intraperitoneal |
14300ug/kg (14.3mg/kg) |
? |
Drugs of the Future. Vol. 14, Pg. 529, 1989. |